Molecular profiling in glioblastoma: prelude to personalized treatment.
The purpose of this review is to provide an up-to-date summary of the current knowledge and understanding of the molecular alterations and pathways relevant to the clinical outcome of glioblastoma patients and their potential use in designing personalized treatment for these patients. This article also discusses the potential of molecular profiling as a diagnostic modality, possible therapeutic implications of MGMT promoter methylation, the targeted inhibition of angiogenesis, and assessment of the tumor's molecular background with respect to PI3K/AKT pathway activation and associated molecules (EGFR, EGFRvIII, PTEN).
Mladkova
Nikol
N
Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
Chakravarti
Arnab
A
D000970:Antineoplastic Agents / Q000494:pharmacology; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism*; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D066246:ErbB Receptors; D005909:Glioblastoma / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D008954:Models, Biological; D009389:Neovascularization, Pathologic; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D011401:Promoter Regions, Genetic; D015398:Signal Transduction; D025521:Tumor Suppressor Proteins / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D000970:Antineoplastic Agents; D010982:Platelet-Derived Growth Factor; D025521:Tumor Suppressor Proteins; D042461:Vascular Endothelial Growth Factor A; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors; D045643:DNA Repair Enzymes